Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone

Clinical Pharmacology and Therapeutics

Volumn 64, Issue 6, 1998, Pages 597-602

  Trapnell, Carol Braun ^a   Donahue, Stephen R ^b   Collins, Jerry M ^c   Flockhart, David A ^c   Thacker, David ^c   Abernethy, Darrell R ^c  

^a ICON Development Solutions   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETHINYLESTRADIOL; MESTRANOL PLUS NORETHISTERONE; NORETHISTERONE; THALIDOMIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; ENZYME INDUCTION; FEMALE; FEMALE STERILIZATION; HUMAN; IMMUNOMODULATION; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL;

AMERICAS; CLINICAL RESEARCH; CONTRACEPTION; CONTRACEPTIVE AGENTS; CONTRACEPTIVE AGENTS, ESTROGEN; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVE AGENTS, PROGESTIN; CONTRACEPTIVE METHODS; DEVELOPED COUNTRIES; DISTRICT OF COLUMBIA; DRUG INTERACTIONS; DRUGS; ETHINYL ESTRADIOL; FAMILY PLANNING; NORETHINDRONE; NORTH AMERICA; NORTHERN AMERICA; ORAL CONTRACEPTIVES; RESEARCH METHODOLOGY; RESEARCH REPORT; TREATMENT; UNITED STATES;

ADULT; AREA UNDER CURVE; CONTRACEPTIVES, ORAL, SYNTHETIC; CROSS-OVER STUDIES; ESTRADIOL CONGENERS; ETHINYL ESTRADIOL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; NORETHINDRONE; PROGESTERONE CONGENERS; THALIDOMIDE;

EID: 0032435953     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90050-9     Document Type: Article

References (27)

1. Günzler V. Thalidomide in human immunodeficiency virus (HIV) patients: a review of safety considerations. Drug Saf 1992;7:116-134.
2. Sheskin J. Thalidomide in the treatment of lepra reactions. Clin Pharmacol Ther 1965;6:303-6.
3. Sampaio EP, Kaplan G, Miranda A. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993;168:408-14.
4. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997;336:1487-93.
5. Revuz J, Guillaume JC, Janier M, et al. Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis. Arch Dermatol 1990;126:923-7.
6. Nicolau DP, West TE. Thalidomide: treatment of severe recurrent aphthous stomatitis in patients with AIDS. Ann Pharmacother 1990;24:1054-6.
7. Oldfield EC. Thalidomide for severe aphthous ulceration in patients with human immunodeficiency virus (HIV) infection [letter]. Am J Gastroenterol 1994;89:2276-7.
8. Weinroth SE, Parenti DM, Simon GL. Wasting syndrome in AIDS: pathophysiologic mechanisms and therapeutic approaches. Infect Agents Dis 1995;4:76-94.
9. Rigby AS, Chamberlain MA, Bhakya B. Behçet's disease. Baillieres Clin Rheumatol 1995;9:375-95.
10. Ziegel J. Angiogenesis research enjoys growth spurt in the 1990s. J Natl Cancer Inst 1996;88:786-8.
11. Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med 1992;326:1055-8.
12. Schwinghammer TL, Bloom EJ. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation. Clin Pharm 1993;12:736-61.
13. Bron D. Graft-versus-host disease. Curr Opin Oncol 1994;6:358-64.
14. Atra E, Sato EI. Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide. Clin Exp Rheumatol 1993;11:487-93.
15. Wiener H, Krivanek P, Tuisl E, Kolassa N. Induction of drug metabolism in the rat by taglutimide, a sedative-hypnotic glutarimide derivative. Eur J Drug Metab Pharmacokinet 1980;5:93-7.
16. Ebner T, Remmel RP, Burchell B. Human bilirubin UDP-glucuronosyltransferase catalyzes the glucuronidation of ethinylestradiol. Mol Pharmacol 1993;43:649-54.
17. Guengerich FP. Oxidation of 17α-ethynylestradiol by human liver cytochrome P-450. Mol Pharmacol 1988;33:500-8.
18. Bolt HM, Kappus H, Bolt M. Effect of rifampicin treatment on the metabolism of oestradiol and 17α-ethinyloestradiol by human liver microsomes. Eur J Clin Pharmacol 1975;8:301-7.
19. Grange JM, Winstanley PA, Davies PD. Clinically significant drug interactions with antituberculosis agents. Drug Saf 1994;11:242-51.
20. Shenfield GM. Oral contraceptives: are drug interactions of clinical significance? Drug Saf 1993;9:21-37.
21. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-58.
22. Tacey RL, Harman WJ, Kelly LL. Development of a highly sensitive and specific assay for plasma ethynylestradiol using combined extraction, liquid chromatography and radioimmunoassay. J Pharm Biomed Anal 1994;12:1303-10.
23. Lee GJ, Oyang MH, Bautista J, Kushinsky S. Determination of ethinylestradiol and norethindrone in a single specimen of plasma by automated high-performance liquid chromatography and subsequent radioimmunoassay. J Liquid Chromatogr 1987;10:2305-18.
24. Eriksson T, Björkman S, Fyge Å. Determination of thalidomide in plasma and blood by high-performance liquid chromatography: avoiding hydrolytic degradation. J Chromatogr 1992;582:211-6.
25. Fotherby K. Variability of pharmacokinetic parameters for contraceptive steroids. J Steroid Biochem Mol Biol 1983;19:817-20.
26. Goldzieher JW. Selected aspects of the pharmacokinetics and metabolism of ethinyl estradiol and their clinical implications. Am J Obstet Gynecol 1990;163:318-22.
27. Humpel M, Nieuweboer B, Wendt H, Speck U. Investigations of pharmacokinetics of ethinyloestradiol to specific consideration of a possible first-pass effect in women. Contraception 1979;17:421-32.